EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Adenomyosis and Abnormal Uterine Bleeding: Review of the Evidence

Marwan Habiba iD, Sun-Wei Guo iD, Giuseppe Benagiano iD

Biomolecules · 23.05.2024 · 14 (6) · 616

DOI: 10.3390/biom14060616 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 23.05.2024. Verfasst von Marwan Habiba und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University of Leicester, Leicester LE1 7RH, UK. Hauptthemen laut MEDLINE: Adenomyosis, Uterine Hemorrhage. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Shenkang Centre for Hospital Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thomas Cullen described bleeding abnormalities and dysmenorrhea as the “expected” presentations of adenomyomas. Adenomyosis is included within the FIGO classification of structural causes of abnormal uterine bleeding (AUB). Nevertheless, this long-standing association has been questioned by some authors who reported a high incidence of adenomyosis in uteri removed for indications other than AUB or dysmenorrhea. Here, we examine evidence for the link between adenomyosis and AUB.

Methods

A comprehensive Medline literature review of all publications to October 2023.

Results

Sixty-three articles were identified and included in the review. Despite a large body of studies, the available literature does not provide conclusive evidence of a link between adenomyosis and AUB. This is because of unsuitable study design, or poor characterization of the study population or of the inclusion or exclusion criteria. Additional challenges arise because of the lack of agreed criteria for diagnosing adenomyosis and the often absence of detailed assessment of menstrual blood loss. Adenomyosis often coexists with other conditions that have also been linked to similar symptoms, and many cases of adenomyosis are asymptomatic.

Conclusion

Most of the existing literature and studies that addressed treatment outcome of adenomyosis started from the premise that a link between the condition and AUB had been proven. Yet, published information shows that aspects such a relationship is still uncertain. Further research is needed to address the relation between AUB and adenomyosis burden (or subtypes), distribution, and concomitant pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenomyosisUterine HemorrhageHumansFemaleDysmenorrhea

Stichwörter der Autor:innen

abnormal uterine bleedingadenomyosismenorrhagiauterine disease

Autor:innen und Institutionen

  • Department of Health Sciences, University of Leicester, Leicester LE1 7RH, UK.
  • Women and Perinatal Services, Leicester Royal Infirmary, Leicester LE1 5WW, UK.
  • Research Institute, Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China.
  • Faculty of Medicine and Surgery, "Sapienza" University of Rome, 00161 Rome, Italy.
  • Geneva Foundation for Medical Education and Research, 1202 Geneva, Switzerland.

ORCID-Profile: Marwan Habiba, Sun-Wei Guo, Giuseppe Benagiano

Förderung

  • National Natural Science Foundation of China
  • Shanghai Shenkang Centre for Hospital Development

Zitieren

APA

Habiba, M., Guo, S. W., & Benagiano, G. (2024). Adenomyosis and Abnormal Uterine Bleeding: Review of the Evidence. Biomolecules, 14(6), 616. https://doi.org/10.3390/biom14060616

Vancouver

Habiba M, Guo SW, Benagiano G. Adenomyosis and Abnormal Uterine Bleeding: Review of the Evidence. Biomolecules. 2024;14(6):616. doi:10.3390/biom14060616

BibTeX
@article{Habiba2024,
  author = {Habiba, Marwan and Guo, Sun-Wei and Benagiano, Giuseppe},
  title = {Adenomyosis and Abnormal Uterine Bleeding: Review of the Evidence},
  journal = {Biomolecules},
  year = {2024},
  volume = {14},
  number = {6},
  pages = {616},
  doi = {10.3390/biom14060616}
}
Kostenlos starten →